UBS Asset Management Americas Inc. Has $104.78 Million Stake in Zimmer Biomet Holdings Inc (ZBH)

UBS Asset Management Americas Inc. lifted its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 29.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 868,316 shares of the medical equipment provider’s stock after purchasing an additional 199,108 shares during the period. UBS Asset Management Americas Inc. owned 0.43% of Zimmer Biomet worth $104,780,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ZBH. Longview Partners Guernsey LTD increased its stake in shares of Zimmer Biomet by 17.7% in the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after purchasing an additional 1,128,973 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Zimmer Biomet by 98.8% in the 4th quarter. Wells Fargo & Company MN now owns 2,044,375 shares of the medical equipment provider’s stock worth $246,695,000 after purchasing an additional 1,016,085 shares in the last quarter. Alyeska Investment Group L.P. increased its stake in shares of Zimmer Biomet by 249.3% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock worth $119,417,000 after purchasing an additional 727,925 shares in the last quarter. Jana Partners LLC increased its stake in shares of Zimmer Biomet by 16.6% in the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after purchasing an additional 662,497 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Zimmer Biomet by 14.7% in the 4th quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock worth $576,488,000 after purchasing an additional 612,044 shares in the last quarter. Hedge funds and other institutional investors own 88.18% of the company’s stock.

Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $118.72 on Wednesday. The firm has a market capitalization of $24,393.96, a PE ratio of 13.18, a PEG ratio of 2.12 and a beta of 1.08. The company has a current ratio of 1.52, a quick ratio of 0.83 and a debt-to-equity ratio of 0.76. Zimmer Biomet Holdings Inc has a 12-month low of $108.03 and a 12-month high of $133.49.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $2.10. The firm had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.03 billion. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.14 earnings per share. sell-side analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Stockholders of record on Friday, December 29th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.81%. Zimmer Biomet’s payout ratio is 10.65%.

In related news, VP Chad F. Phipps sold 20,826 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $115.95, for a total value of $2,414,774.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Bryan C. Hanson purchased 25,077 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was acquired at an average cost of $119.68 per share, with a total value of $3,001,215.36. The disclosure for this purchase can be found here. Company insiders own 1.07% of the company’s stock.

A number of brokerages have issued reports on ZBH. Jefferies Group reiterated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. SunTrust Banks increased their price target on Zimmer Biomet to $142.00 and gave the stock a “buy” rating in a research note on Monday, January 29th. Stifel Nicolaus reiterated a “hold” rating and issued a $120.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. TheStreet lowered Zimmer Biomet from a “b-” rating to a “c+” rating in a research note on Friday, November 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zimmer Biomet in a research note on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Zimmer Biomet presently has a consensus rating of “Buy” and an average price target of $141.67.

WARNING: This news story was first reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://weekherald.com/2018/02/21/ubs-asset-management-americas-inc-has-104-78-million-stake-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply